Regulatory & Reimbursement Decisions Database for Innovative Drugs to Improve Consistency of Decision-Making

Abstract

A741process timelines, requested reimbursement mode, STC, RPA, MoHD, discrepancy between requested conditions and MoHD, information from BIA and ICER value if applicable, and key findings from available clinical analyses. ConClusions: Health care systems based on public money should treat all applicants equally if the conditions for the decision are similar and should provide equal access to benefits for patients with similar needs. The database gathers information on all precedent decisions of marketing authorization and public payer practices of similar products or similar indications. This approach opens up the possibility for improvement of transparency and decision-making practices not only in Poland, but in each country. PRM62CoMPaRison of iCd-9 to iCd-10 CRosswalks deRived By PhysiCian and CliniCal CodeR vs. autoMated Methods